Centene stock has delivered a strong 1 year return while the current valuation checks still point to the shares screening as undervalued on several metrics. This raises the question of how much of that gain is already reflected in the current US$63.41 price.

• Over the last 1 year, Centene is up 123.4%, which puts recent buyers in profit and makes the current valuation more important for anyone considering new capital.
• Future growth in membership and medical cost control can support earnings, but any disappointment around margins or higher than expected healthcare costs may quickly change how the stock is priced.
• Centene screens as undervalued in 5 of 6 key checks, giving it a high valuation score here and suggesting the broader indicators still lean cheap rather than expensive.

The issue now is whether Centene's recent share price strength has already captured most of that apparent valuation upside or still leaves room for further gains supported by fundamentals.

Is Centene Still Cheap on Sales?

The P/S multiple suits Centene because revenue is a core yardstick for health insurers where margins can be tightly managed and regulated. At the current share price of about US$63.41, Centene trades on a P/S of roughly 0.2x, compared with a Healthcare industry average of about 1.4x and a broader peer group average of about 1.7x.

The Fair Ratio model, which looks at Centene’s growth profile, margins, size and risk, suggests a P/S closer to 0.9x. That is well above the current level, so the stock screens at a sizeable discount even after the recent share price move. For investors who focus on revenue based benchmarks, Centene’s current P/S leaves a wide gap between the traded multiple and what the model implies could be reasonable for the business.

On the P/S multiple, Centene stock appears undervalued compared with both its tailored Fair Ratio and typical Healthcare peers.

The Centene Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Centene pick up where this valuation puzzle leaves off by explaining which combinations of growth, margins and earnings would need to hold for Centene's stock to be worth materially more or less than today’s price, using scenarios that sit on the Community page. Each one links a fair value estimate to a specific story about Centene's potential catalysts and risks, so you can monitor over time which version of events appears to be unfolding.

Community views on Centene sit far apart, with one camp leaning toward recovery potential and the other focused on policy and margin risks.

Bull case: roughly fairly valued

"Increased 2025 Medicare Advantage membership expectations, driven by higher retention rates, contribute to an upward revision in annual revenue, supporting earnings growth prospects..."

Bear case: 59% overvalued

"Rising government scrutiny over managed care costs and ongoing legislative focus on pricing transparency are set to intensify regulatory pressure on Centene, increasing the risk of lower reimbursement rates and margin compression..."

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

The Bottom Line

For now, Centene still screens as undervalued on market multiples, even after a strong 1 year share price move. That discount hinges on whether revenue, membership and medical costs track close to the scenarios that support a higher P/S, or whether policy and margin pressure pull the market back toward the bear case. The crux for you is simple: the current gap between Centene's traded multiple and its implied fair ratio either represents mispricing that closes over time or a value trap if reimbursement and cost trends break against the company.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.